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34 In this retrospective cohort study we aimed to assess whether introducing benznidazole at 
35 escalating doses reduces the probability of adverse events or treatment discontinuation 
36 compared to a full dose scheme. We collected data from patients who had chronic T.cruzi 
37 infection and underwent treatment from July 2008 to January 2017 in a referral centre in 
38 Madrid. Dose was adjusted to body weight (5mg/kg/day), with treatment introduction with 
39 full dose or escalating dose according to local consensus and protocols. 
40 Among the 62 patients treated, benznidazole was introduced at full dose in 28 patients and 
41 on escalating dose in the remaining 34. We found no statistical differences in the number of 
42 adverse events, treatment discontinuations, days of treatment or socio-demographic 
43 profiles. There is insufficient evidence to support escalating dose as a strategy for reducing 
44 adverse effects of benznidazole. Further research is needed in order to evaluate this 
45 strategy.




48 Chagas disease is a zoonosis caused by the parasite Trypanosoma cruzi. The World Health 
49 Organization (WHO) estimates that there are 6-7 million people infected worldwide.1 Most 
50 cases are in endemic regions of Latin America but an increasing number of cases are being 
51 diagnosed in other countries (mainly the United States and southern Europe) due to 
52 migration.2-4 In endemic areas, the primary vector for transmission is the triatomine bug, 
53 whose presence in households has been related to substandard building construction. Other 
54 means of transmission in endemic and non-endemic countries are vertical (mother to child) 
55 and parenteral transmission through blood transfusion and organ transplantation. After a 
56 typically self-limited acute phase with unspecific symptoms (therefore difficult to diagnose), 
57 the disease enters a chronic phase in which organ complications (mostly cardiac and 
58 digestive) occur in approximately one-third of patients.5
59 The therapeutic options available for antiparasitic treatment of Chagas disease have 
60 remained unchanged for around 50 years. The only two available treatments are nifurtimox 
61 and benznidazole, which were introduced in 1965 and 1971 respectively.6
62 The efficacy of these treatments is highly variable, since it is affected by the drug dose, 
63 disease stage, and the age and area of origin of the patient, among other factors. Cure rates 
64 between 60% and 100% are reported when treatment with benznidazole is provided in the 
65 acute phase and in younger patients.7-9 The antiparasitic effect of the treatment in the 
66 chronic phase is well documented.10-14 However, clinical effectiveness (defined as reduction 
67 in clinical events) is still the subject of intense scientific debate.15 Treatment with 
68 antitrypanosomal drugs is currently indicated in acute infection, congenital infection, 
69 reactivations and chronic infection in children under 18 years of age. Although in recent 
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70 years there seems to be some consensus regarding the absence of benefit of antiparasitic 
71 treatment in patients with advanced forms of cardiac or digestive involvement, most 
72 national and regional guidelines recommend offering treatment in the indeterminate 
73 chronic phase,16,17 as well as in patients with mild to moderate determinate disease.
74 The biggest challenge associated with the available antitrypanosomal drugs is their safety 
75 profile. From 48% to 86% of patients experience adverse effects of benznidazole, with the 
76 result that treatment discontinuation occurs in 9% to 31% of cases.18-21 This further limits 
77 global treatment coverage, which is already low given that only 4% to 6% of migrants with 
78 Chagas disease are aware of their condition4 and that treatment reaches less than 1% of 
79 patients with Chagas disease.22-25 The most frequently observed adverse events are 
80 dermatological, gastro-intestinal and neurological, usually mild and with acceptable 
81 response to symptomatic treatment or to benznidazole discontinuation.18-21 Serious adverse 
82 events such as DRESS syndrome are rare, and life-threatening conditions such as severe 
83 neutropenia are extremely uncommon.18-21,26 
84 Alongside the search for new and better tolerated drugs,14,27-29 efforts are being made to 
85 increase the tolerability of existing antitrypanocidal drugs.30 Studies aimed at identifying risk 
86 factors for adverse responses to benznidazole have found associations with female sex,21 
87 graduation from elementary school, and white and mulatto race.31 Additionally, carrying 
88 HLA-B*3505 allele could be associated with moderate to severe cutaneous
89 reaction.32 Another study found that adverse events, female sex, drug dose and eosinophilia 
90 were the main predictors of treatment interruption.33 A study attempting to find a 
91 measurable proxy for toxicity failed to correlate adverse events with serum concentrations 
92 of benznidazole.34 Some researchers have proposed the use of corticosteroid therapy along 
93 with benznidazole35 to prevent cutaneous reactions. However, this strategy failed to show a 
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94 clear advantage and raised concerns because of the high rate of Strongyloides stercoralis 
95 coinfection in patients with Chagas disease36 and risk of hyperinfection syndrome. A clinical 
96 trial evaluating shorter regimes and lower dosing of benznidazole is expected to soon 
97 provide some insight on the feasibility of this strategy.37 Moreover, some researchers have 
98 proposed the use of escalating doses of benznidazole during the first days of treatment in 
99 order to increase its tolerability.38 However, this strategy has not been compared to 
100 standard treatment with full (adjusted to weight) doses from the beginning of treatment. 
101
102 In this study we aim to ascertain whether introducing benznidazole at progressively higher 
103 dose until the target daily dose is reached reduces the probability of adverse events or 
104 treatment discontinuation. 
105
106 Methods
107 In this retrospective cohort study we reviewed clinical records of patients referred to the 
108 Infectious Diseases department in Hospital 12 de Octubre (Madrid, Spain) from July 2008 to 
109 January 2017. Inclusion criteria were chronic infection with T.cruzi as defined by WHO 
110 criteria (two positive serological tests)39, age 18 years or older and previous treatment with 
111 benznidazole in our center. (Those who were receiving it at the time of data collection were 
112 excluded.) 
113 The usual evaluation of these patients includes a questionnaire about their country of origin 
114 and risk factors for Chagas disease. The patient’s medical history is obtained and a physical 
115 examination aimed at detecting cardiac or digestive involvement is performed. 
116 Electrocardiogram and echocardiogram are routinely performed to rule out cardiac 
Page 5 of 46 American Journal of Tropical Medicine & Hygiene
6
117 involvement. Tests to rule out digestive tract involvement are carried out according to 
118 symptoms.
119 In the evaluated time frame, some patients began treatment with benznidazole at full doses 
120 and others at progressive doses according to local protocols or consensus when the former 
121 were lacking. Changes in schemes of benznidazole treatment took place over time, both 
122 before and after the first protocol was launched in 2011. Thus, we divided the patients into 
123 two groups, according to the method of introduction of benznidazole treatment. In all cases, 
124 the standard dose of 5 mg per kilogram of body weight was calculated, and then the 
125 treatment was started according to the physicians’ criteria. The maximum daily dose was 
126 300mg in the majority of patients, although some received 250mg and others 400mg. In the 
127 full-dose group, the previously calculated dose was divided into two daily doses for 60 days. 
128 In the progressive dose group, treatment was started with 50mg per day (half a tablet), then 
129 increased by 50mg every day until the correct dosage according to weight was reached. 
130
131 Statistical analysis: categorical variables were described by frequencies and percentages. 
132 Quantitative variables were described as means and standard deviations or medians and 
133 interquartile ranges. A chi-square test or Fisher’s exact test was used to compare qualitative 
134 variables. Student’s t test was used to compare normally distributed continuous variables, 
135 and Mann-Whitney U test was used to compare non-normally distributed variables with 
136 qualitative variables. Statistical significance was set at P< 0.05. Data analysis was performed 
137 using Stata15 (Stata Corp., College Station, TX). 
138
139 This work was submitted and approved under number 17/051 by the Research Ethics 
140 Committee of Hospital 12 de Octubre, Madrid, Spain.




143 In this study a total of 62 patients were treated with benznidazole adjusted to body weight 
144 either on a full dose from the start or with an escalating dose regime. As shown in Table 1, 
145 the two groups did not differ in baseline characteristics, comorbidities or clinical stage of 
146 Chagas disease. A large majority of patients were from Bolivia (97%). One patient in the full-
147 dose group was from Honduras, and one patient who received escalating dose treatment 
148 was from Brazil. 
149 The median maximum daily dose was approximately 300mg, without differences between 
150 groups. 
151 There were no significant differences between groups regarding the occurrence of adverse 
152 events (Table 2). At least one adverse event was observed in 88.7% of patients, with no 
153 differences between groups. The most frequent disturbances were cutaneous (61.3%). The 
154 second most frequent adverse reactions were neuromuscular (50%) which included 
155 headache, vertigo, insomnia, polyneuropathy, paresthesia, arthralgia and myalgia. Other 
156 disturbances (hematologic, liver, digestive and renal) occurred in smaller percentages of 
157 patients on both groups. 
158 Treatment interruption due to adverse events occurred in 33.9% of all patients. Mean 
159 number of treatment days was 50.5 (sd 18.9), with no differences between groups (Figure 
160 1). Adverse events leading to early interruption (when established at 50% or 80% of total 
161 dose), occurred in 3 to 5 of 25 patients on the full dose group, and in 7 to 11 of 29 patients 
162 of the escalating dose group. That is to say that 18.5 to 29.6% of adverse events (depending 
163 on the 'early interruption' threshold used) led to early interruption of treatment that would 
164 need further antiparasitic treatment. Patients were referred to a specialist because of an 
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165 adverse event in 43.5% of cases, with dermatology (85%), neurology (11%) and allergy (4%) 
166 being the most frequent. Specific treatment for an adverse event was prescribed in 42% of 




171 To our knowledge, this is the first study to compare how the strategy of progressively 
172 introducing benznidazole compares to initiating treatment at a full dose. We could not find 
173 any significant differences in the rate of adverse effects, treatment discontinuations or 
174 number of treatment days completed, although the results showed numerically fewer 
175 hematologic, liver, and digestive disturbances in the escalating dose group. Although 
176 adverse events were not systematically rated for severity, it is possible to ascertain through 
177 indirect data such as need for specific treatment and need for treatment discontinuation 
178 that they were mostly mild. We found an unusually high referral rate to a specialist for 
179 adverse events (43.55%), which is not related to severity but to a local agreement of 
180 multidisciplinary evaluation of all benznidazole adverse events.
181 The global adverse event rate for benznidazole is in agreement with previous work, 
182 although we found a slightly higher rate of discontinuation than previous studies.18-21 With 
183 such a high rate of adverse events, an intervention such as the progressive introduction of 
184 the same drug is unlikely to yield mayor advantages. Hence, a larger sample size would be 
185 needed to detect whether these two treatment strategies yield different outcomes. 
186 There is currently no consensus regarding the ideal treatment schedule with benznidazole in 
187 terms of length, especially after it has been necessary to discontinue treatment. Some 
188 groups consider it sufficient to have received 30 days and others 80% of the dose calculated 
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189 for 60 days10,40. In our study, the median duration of treatment in both groups exceeds even 
190 the most ambitious threshold of 48 days (80%). This means that although suspension is 
191 necessary in a high percentage of patients, treatment with a second drug would not be 
192 indicated in most of them due to having met the minimum dose requirement. As shown in 
193 Figure 1, most treatment discontinuations occurred after previously mentioned thresholds 
194 of 30 and 48 days. This is because clinicians would be more prone to discontinue treatment 
195 when a mild adverse event occurs after a sufficient duration of antiparasitic treatment has 
196 been reached, taking into account the risk/benefit balance. 
197 The retrospective nature of this study and the fact that these two different strategies were 
198 put in place by different physicians may have introduced some measurement bias. Given 
199 that the patients were assigned to each doctor according to availability (without choice by 
200 the doctor or the patient), and treatments assigned according to local protocols (or 
201 consensus) at each point in time, we think that this would not constitute a source of 
202 selection bias. Nonetheless, data were collected using electronic medical records by 
203 different physicians than the ones who treated the patients, in order to increase objectivity. 
204 Each time a benznidazole treatment is started, it constitutes both an opportunity and a 
205 challenge. Any doctor faced with this situation longs for alternatives that improve the safety 
206 of antiparasitic treatment, either with new drugs, dosing changes in existing drugs, or the 
207 use of adjuvant drugs. With currently available data, it cannot be asserted that a strategy of 
208 progressive doses is better than the use of full doses from the beginning. However, 
209 prospective randomized studies are needed to improve knowledge about this issue, given 
210 the possibility that different benznidazole treatment introduction strategies might improve 
211 tolerability and therefore might improve patient health outcomes.
212
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255
256 Table 1. Baseline characteristics
257
CHARACTERISTICS FULL DOSE (N=28) ESCALATING DOSE (N= 34) p
Age - mean years (sd) 40.7 (8.9) 39.7 (8.2) 0.68
Male sex - no. (%) 7 (25%) 12 (35.3%) 0.38
Habits
Smoker- no. (%) 3/18 (16.7%) 6/22 (27.3%) 0.42
Alcohol consumption - no. (%) 2/19 (10.5%) 6/22 (27.3) 0.18
Comorbidities
Hypertension - no. (%) 1 (3.6%) 1 (2.9%) 0.89
Diabetes - no. (%) 1 (3.6%) 0 (0%) 0.27
Obesity - no. (%) 3/26 (11.5%) 2/33 (6.1%) 0.45
Cerebrovascular disease - no. (%) 1 (3.6%) 1 (2.9%) 0.89
Liver disease - no. (%) 0  1 (2.9%) 0.36




     Indeterminate form 22 (78.6%) 25 (73.5%) 0.64
     Cardiac form - no. (%) 6 (21.4%) 9 (26.4%) 0.64
     Gastrointestinal form -no. (%) 0 0
no: number, sd: standard deviation
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262
263 Table 2. Adverse events
264





At least one adverse event - no. (%) 25 (89.29) 29 (85.29) 0.64
Skin disturbances - no. (%) 17 (60.71) 21 (61.76) 0.93
Neuromuscular side effects - no. (%) 15 (53.57) 16 (47.06) 0.61
Hematologic toxicity - no. (%) 7 (25) 5 (14.71) 0.24
Liver toxicity - no. (%) 7 (25) 5 (14.71) 0.24
Digestive disturbances - no. (%) 7 (25) 3 (8.82) 0.08
Kidney injury - no. (%) 0 1 (2.94) 1
MANAGEMENT
Need of specific treatment - no. (%) 12 (42.86) 14 (41.18) 0.89
Referral to a specialist - no. (%) 12 (42.86) 15 (44.12) 0.92
Hospital admission - no. (%) 1 (3.57) 2 (5.88) 0.67
Treatment interruption - no. (%) 7 (25) 14 (41.18) 0.18
Treatment duration, days (sd) 51.75 (15.4) 49.4 (21.5) 0.26
Completed at least 80% of total dose - no. (%) 21 (75) 23 (67.65) 0.53
Completed at least 30 days- no. (%) 25 (89.29) 27 (79.41) 0.29
Maximum dose per day, median grams (sd) 316.1 (38.7) 304.5 (26.1) 0.14
no: number, sd: standard deviation
265
266
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269 Figure 1. Time to permanent treatment discontinuation
270
271
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35 In this retrospective cohort study we aimed at assessingto assess whether introducing 
36 benznidazole at escalating doses reduces the probability of adverse events or treatment 
37 discontinuation compared to a full dose scheme. We collected data of from patients with 
38 who had chronic T.cruzi infection with and underwent treatment T.cruzi treated with 
39 benznidazole from July 2008 to January 2017 in a referral centre in Madrid. Dose were was 
40 adjusted to body weight (5mg/kg/day), with treatment introduction with full dose or 
41 escalating dose according to local consensus and protocols. 
42 Of Among the 62 patients treated in this period, benznidazole was introduced at full dose in 
43 28 patients and on escalating dose in the remaining 34. We found no statistical differences 
44 in the number of adverse events, treatment discontinuations, days of treatment or socio-
45 demographic profiles. There is not enoughinsufficient evidence supporting to support 
46 escalating dose as a strategy to reduce for reducing adverse events effects of benznidazole. 
47 Further research is needed in order to evaluate this strategy.




50 Chagas’ disease (CD) is a zoonosis caused by the parasite Trypanosoma cruzi. WHO (The 
51 World Health Organization (WHO) estimates that there are 6-7 million people infected 
52 worldwide,.1 mostly inMost cases are in endemic regions of Latin America but an increasing 
53 number of cases are being diagnosed in other countries (mainly USA the United States and 
54 southern Europe) due to migratory flowsmigration.2-4 In endemic areas, the primary vector 
55 for transmission occurs primarily throughis the triatomine bug vector, whose presence in 
56 the households has been related to substandard building constructionpoor housing. Other 
57 means of transmission present in endemic and non-endemic countries are vertical (mother 
58 to child) and parenteral transmission through blood transfusions and organ transplantation. 
59 After a usually typically self-limited acute phase with unspecific symptoms (therefore 
60 difficult to suspect and diagnose), the disease evolves tonters a chronic phase that can lead 
61 toin which organ complications (mostly cardiac and digestive) on occur in approximately 
62 one- third of the patients.5
63 The therapeutic options available for antiparasitic treatment of Chagas disease have 
64 remained unchanged for around 50 years. The only two available therapeutic alternatives 
65 reatments are nifurtimox and benznidazole, which were released introduced in 1965 and 
66 1971 respectively.6
67 The reported efficacy of these treatments is very highly variable, since it is affected by the 
68 drug dose, the stage of the diseasedisease stage, and the age and area of origin of the 
69 patient, among other factorss. Cure rates between 60% and 100% are reported when 
70 treatment with benznidazole is provided in the acute phase and in younger patients.7-9 The 
71 antiparasitic effect of the treatment in the chronic phase is well documented. 10-14. 
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72 However, clinical effectiveness (defined as reduction in clinical events) is still the subject of 
73 intense scientific debate.15 Treatment with antitrypanosomal drugs is currently indicated in 
74 acute infection, congenital infections, reactivationss and chronic infection in children under 
75 18 years of age. Although in recent years there seems to be some consensus in regarding 
76 the absence of benefit of antiparasitic treatment in patients with advanced forms of cardiac 
77 or digestive involvement, most national and regional guidelines recommend offering 
78 treatment in the indeterminate chronic phase,16,17 and as well as in patients with mild to -
79 moderate determinate disease.
80 The biggest challenge associated with the available antitrypanosomal drugs is their safety 
81 profile. A rate of adverse effects of benznidazole ranging fFrom 48% to 86% of patients 
82 experience adverse effects of benznidazole, with the result that leads to treatment 
83 discontinuation occurss in 9% to -31% of cases.18-21 This further jeopardizes limits the 
84 already slim global antiparasitic treatment coverage of patients with CD,, which is already 
85 low given that only 4% to -6% of migrants with ChagasD disease are aware of their 
86 condition4 and the that CD treatment coverage rate reaches less than 1% of patients with 
87 Chagas diseaseD.22-25 The most frequently observed adverse events are dermatological, 
88 gastro-intestinal and neurological, usually mild and with acceptable response to 
89 symptomatic treatment or to benznidazole discontinuation.18-21 Serious adverse events such 
90 as DRESS syndrome are rare, and life-threatening conditions such as severe neutropenia are 
91 extremely uncommon.18-21,26 
92 Along withside the search for new and better tolerated drugs,14,27-29 efforts are been being 
93 made in order to increase the tolerability of existing antitrypanocidal drugs.30 Some sStudies 
94 aimed at finding identifying risk factors for adverse responses to benznidazole found an 
95 association of adverse eventshave found associations with female sex,21 graduation from 
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96 elementary school, and white and mulatto race.31 Additionally, carrying HLA-B*3505 allele 
97 could be associated with moderate to -severe cutaneous
98 reaction.32 Another study found that adverse events, female sex, drug dose and eosinophilia 
99 where the main predictors for of treatment interruption.33 Likewise, an attemptA study 
100 attempting to find a measurable proxy for toxicity failed to correlate adverse events with 
101 serum concentrations of benznidazole.34 Some groups researchers have proposed the use of 
102 corticosteroid therapy along with benznidazole35 to prevent cutaneous reactions. However, 
103 this strategy failed to show a clear advantage and raised some concerns because of the high 
104 rate of Strongyloides stercoralis coinfection in patients with CD36 Chagas disease36 and risk 
105 of hyperinfection syndrome. A clinical trial where evaluating shorter regimes and lower 
106 dosing of benznidazole are been evaluated willis expected to soon provide some insight on 
107 the feasibility of this strategy.37 Moreover, some groups researchers have proposed the use 
108 of escalating doses of benznidazole during the first days of treatment in order to increase its 
109 tolerability.38 However, this strategy has not been compared to standard treatment with full 
110 (adjusted to weight) doses from the beginning of treatment. 
111
112 In this study we aim to ascertain whether introducing benznidazole at progressively higher 
113 dose until the target daily dose is reached reduces the probability of adverse events or 
114 treatment discontinuation. 
115
116 Methods
117 In this retrospective cohort study we reviewed clinical records of patients referred to the 
118 Infectious Diseases department who fulfilled WHO criteria of T.cruzi infection (two positive 
119 serological tests)39  in Hospital 12 de Octubre (Madrid, Spain) from July 2008 to January 
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120 2017. Inclusion criteria were: chronic infection by with T.cruzi as defined by WHO criteria 
121 (two positive serological tests)39, age over 18 years or older and having receivedprevious 
122 treatment with benznidazole in our center. ( excluding tThose who were receiving it at the 
123 time of data collection were excluded.). 
124 The usual evaluation of these patients includes a questionnaire about their country of origin 
125 and risk factors for Chagas disease. The patient’s medical history is obtained Anamnesis and 
126 a physical examination aimed at detecting cardiac or digestive involvement are is 
127 performed. Electrocardiogram and echocardiogram are routinely performed to rule out 
128 cardiac involvement. Tests to rule out digestive tract involvement are carried out according 
129 to symptoms.
130 In the evaluated time frame, some of the patients began treatment with benznidazole at full 
131 doses and others at progressive doses according to local protocols or consensus when the 
132 former were lacking. Changes in schemes of benznidazole treatment took place over time, 
133 both before and after the first protocol was launched in 2011. Thus, we divided the patients 
134 into two groups, according to the method of introduction of benznidazole treatment. In all 
135 cases, the standard dose of 5 mg per kilogram of body weight was calculated, and then the 
136 treatment was started according to the physicians’ criteria. The maximum daily dose was 
137 300mg in the majority of patients, although some received 250mg and others 400mg. In the 
138 full- dose group, the previously calculated dose was divided into two daily doses for 60 days. 
139 In the progressive dose group, treatment was started with 50mg per day (half a tablet), then 
140 increased by 50mg every day until the correct dosage according to weight was reached. 
141
142 Statistical analysis: categorical variables were described by frequencies and percentages. 
143 Quantitative variables were described as means and standard deviations or medians and 
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144 interquartile ranges. A chi-square test or a Fisher’s exact test were was used to compare 
145 qualitative variables. SA student’s t test was used when comparingto compare normally 
146 distributed continuous variables, and Mann-Whitney U test to comparewas used to 
147 compare non-normally distributed variables with qualitative variables. Statistical 
148 significance was set at P< 0.05. Data analysis was performed using Stata15 (Stata Corp., 
149 College Station, TX). 
150
151 This work was submitted and approved under number 17/051 by the Research Ethics 
152 Committee of Hospital 12 de Octubre, Madrid, Spain.
153
154 Results
155 In this study a total of 62 patients were treated with benznidazole adjusted to body weight 
156 either on a full dose from the start or with an escalating dose regime. As shown in Table 1, 
157 both the two groups did not differ in baseline characteristics, comorbidities or CD clinical 
158 stage of Chagas disease. A large majority of patients were from Bolivia (97%), one. One 
159 patient in the full-dose group was from Honduras and was allocated in the full dose group, 
160 and one  and the remaining patient was from Brazil andwho received escalating dose 
161 treatment was from Brazil. 
162 The median maximum daily dose was around approximately 300mg, without differences 
163 between groups. 
164 There were no significant differences between groups regarding the occurrence of adverse 
165 events (Table 2). At least one adverse event was observed in 88.7% of the patients, with no 
166 differences between groups. The most frequent disturbances were cutaneous (61.3%). The 
167 second most frequent adverse reactions were neuromuscular (50%) which included 
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168 headache, vertigo, insomnia, polyneuropathy, paresthesia, arthralgia and myalgia. The 
169 restOther of the  disturbances (hematologic, liver, digestive and renal) occurred in a 
170 similarsmaller percentages of patients, maintaining the absence of differences between on 
171 both groups. 
172 Treatment interruption due to adverse events occurred in 33.9% of all patients and m. 
173 Mean number of treatment days was 50.5 (sd 18.9), with no differences between groups 
174 (Figure 1). Adverse events leading to early interruption (when established at 50% or/ 80% of 
175 total dose), where occurred in 3 to /5 of 25 patients on the full dose group, and in 7 to /11 
176 of 29 patients of the escalating dose group.; Tthat is to say that 18.5 to /29.6% of adverse 
177 events (depending on the 'early interruption' threshold used) of adverse events led to early 
178 interruption of treatment that would need further antiparasitic treatment. Patients were 
179 referred to a specialist because of an adverse event in 43.5% of the cases, with Dermatology 
180 dermatology (85%), Neurology neurology (11%) and Allergy allergy (4%) being the most 
181 frequent. Specific treatment for an adverse event was prescribed in 42% of subjectspatients, 




186 To our knowledge, this is the first comparative study between strategiesto compare how 
187 the strategy of progressive introduction ofprogressively introducing benznidazole and 
188 compares to initiating treatment at a full dosefull doses. We could not find any significant 
189 differences in the rate of adverse effects, treatment discontinuations or number of 
190 treatment days completed, although the results showed numerically fewer hematologic, 
191 liver, and digestive disturbances in the escalating dose group. Although adverse events were 
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192 not systematically rated for severity, it is possible to ascertain through indirect data such as 
193 need for specific treatment and need for treatment discontinuation that they were mostly 
194 mild. We found an unusually high referral rate to a specialist for adverse events (43.55%), 
195 which is not related to severity but to a local agreement of multidisciplinary evaluation of all 
196 benznidazole adverse events.
197 The global adverse event rate to for benznidazole is in agreement with previous work, 
198 although we found a slightly higher rate of discontinuation than previous studies.18-21 With 
199 such a high rate of adverse events, an intervention such as thelike a progressive 
200 introduction of the same drug is unlikely to yield mayor advantages. Hence, a bigger larger 
201 sample size would be needed to observe a difference between these two strategies, if 
202 anydetect whether these two treatment strategies yield different outcomes. 
203 There is currently no consensus regarding the ideal treatment schedule with benznidazole in 
204 terms of length, especially when after it has been necessary to discontinue treatment. Some 
205 groups consider it sufficient to have received 30 days and others 80% of the dose calculated 
206 for 60 days10,40. In our study, the median duration of treatment in both groups exceeds even 
207 the most ambitious threshold of 48 days (80%). This means that, although suspension is 
208 necessary in a high percentage of patients,; treatment with a second drug would not be 
209 indicated in most of them due to having met the minimum dose requirement. As shown in 
210 Ffigure 1, most treatment discontinuations occurred after previously mentioned thresholds 
211 of 30 and 48 days. This is because clinicians would be more prone to discontinue treatment 
212 when a mild adverse event occurs after a sufficient length duration of antiparasitic 
213 treatment has been reached, taking into account the risk/benefit balance. 
214 The retrospective nature of this study and the fact that these two different strategies were 
215 put in place by different physicians may have introduced some measuring measurement 
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216 bias. Given that the patients were assigned to each doctor according to availability (without 
217 choice by the doctor or the patient), and treatments assigned according to local protocols 
218 (or consensus) at each point in time, we think that this would not constitute a source of 
219 selection bias. Nonetheless, data were collected using electronic medical records by 
220 different physicians than the ones who treated the patients, in order to improve increase 
221 objectivity. 
222 Each time a benznidazole treatment is started, it constitutes both an opportunity and a 
223 challenge. Any doctor faced with this situation longs forto find alternatives that improve the 
224 safety of antiparasitic treatment, either with new drugs, changing the posology of existing 
225 onesdosing changes in existing drugs, or through the use of adjuvant drugs. In spite of that, 
226 Wwith currently available data, it cannot be asserted that a strategy of progressive doses is 
227 better than the use of full doses from the beginning. However, prospective randomized 
228 studies are needed to improve the knowledge on this fieldabout this issue, given the 
229 possibility that different strategies of  benznidazole treatment introduction strategies might 
230 improve tolerability and therefore might improve patient health outcomes.. 
231
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276 Table 1. Baseline characteristics
277
CHARACTERISTICS FULL DOSE (N=28) ESCALATING DOSE (N= 34) p
Age - mean years (sd) 40.7 (8.9) 39.7 (8.2) 0.68
Male sex - no. (%) 7 (25%) 12 (35.3%) 0.38
Habits
Smoker- no. (%) 3/18 (16.7%) 6/22 (27.3%) 0.42
Alcohol consumption - no. (%) 2/19 (10.5%) 6/22 (27.3) 0.18
Comorbidities
Hypertension - no. (%) 1 (3.6%) 1 (2.9%) 0.89
Diabetes - no. (%) 1 (3.6%) 0 (0%) 0.27
Obesity - no. (%) 3/26 (11.5%) 2/33 (6.1%) 0.45
Cerebrovascular disease - no. (%) 1 (3.6%) 1 (2.9%) 0.89
Liver disease - no. (%) 0  1 (2.9%) 0.36




     Indeterminate form 22 (78.6%) 25 (73.5%) 0.64
     Cardiac form - no. (%) 6 (21.4%) 9 (26.4%) 0.64
     Gastrointestinal form -no. (%) 0 0
no: number, sd: standard deviation
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283 Table 2. Adverse events
284





At least one adverse event - no. (%) 25 (89.29) 29 (85.29) 0.64
Skin disturbances - no. (%) 17 (60.71) 21 (61.76) 0.93
Neuromuscular side effects - no. (%) 15 (53.57) 16 (47.06) 0.61
Hematologic toxicity - no. (%) 7 (25) 5 (14.71) 0.24
Liver toxicity - no. (%) 7 (25) 5 (14.71) 0.24
Digestive disturbances - no. (%) 7 (25) 3 (8.82) 0.08
Kidney injury - no. (%) 0 1 (2.94) 1
MANAGEMENT
Need of specific treatment - no. (%) 12 (42.86) 14 (41.18) 0.89
Referral to a specialist - no. (%) 12 (42.86) 15 (44.12) 0.92
Hospital admission - no. (%) 1 (3.57) 2 (5.88) 0.67
Treatment interruption - no. (%) 7 (25) 14 (41.18) 0.18
Treatment duration, days (sd) 51.75 (15.4) 49.4 (21.5) 0.26
Completed at least 80% of total dose - no. (%) 21 (75) 23 (67.65) 0.53
Completed at least 30 days- no. (%) 25 (89.29) 27 (79.41) 0.29
Maximum dose per day, median grams (sd) 316.1 (38.7) 304.5 (26.1) 0.14
no: number, sd: standard deviation
285
286
Page 36 of 46American Journal of Tropical Medicine & Hygiene
15
288
289 Figure 1. Time to permanent treatment discontinuation
290
291
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Figure 1. Time to permanent treatment discontinuation 
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